These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8558425

  • 1. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [Abstract] [Full Text] [Related]

  • 2. Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.
    Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C.
    Eur J Pharmacol; 1996 Dec 19; 317(2-3):183-90. PubMed ID: 8997599
    [Abstract] [Full Text] [Related]

  • 3. (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).
    Michaelides MR, Hong Y, DiDomenico S, Asin KE, Britton DR, Lin CW, Williams M, Shiosaki K.
    J Med Chem; 1995 Sep 01; 38(18):3445-7. PubMed ID: 7658429
    [No Abstract] [Full Text] [Related]

  • 4. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R, Bédard PJ, Britton DR, Shiosaki K.
    Neurology; 1997 Aug 01; 49(2):421-6. PubMed ID: 9270571
    [Abstract] [Full Text] [Related]

  • 5. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
    Asin KE, Domino EF, Nikkel A, Shiosaki K.
    J Pharmacol Exp Ther; 1997 Apr 01; 281(1):454-9. PubMed ID: 9103530
    [Abstract] [Full Text] [Related]

  • 6. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1999 Feb 01; 142(1):51-60. PubMed ID: 10102782
    [Abstract] [Full Text] [Related]

  • 7. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
    Gleason SD, Witkin JM.
    Behav Pharmacol; 2004 Feb 01; 15(1):85-9. PubMed ID: 15075630
    [Abstract] [Full Text] [Related]

  • 8. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
    Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb 01; 117(3):275-86. PubMed ID: 7770603
    [Abstract] [Full Text] [Related]

  • 9. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M.
    Eur J Pharmacol; 1992 Dec 15; 229(2-3):203-9. PubMed ID: 1362704
    [Abstract] [Full Text] [Related]

  • 10. Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
    Michaelides MR, Hong Y, DiDomenico S, Bayburt EK, Asin KE, Britton DR, Lin CW, Shiosaki K.
    J Med Chem; 1997 May 23; 40(11):1585-99. PubMed ID: 9171869
    [Abstract] [Full Text] [Related]

  • 11. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb 23; 117(3):287-97. PubMed ID: 7770604
    [Abstract] [Full Text] [Related]

  • 12. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
    Fenu S, Espa E, Pisanu A, Di Chiara G.
    Eur J Pharmacol; 2016 Oct 05; 788():183-191. PubMed ID: 27343381
    [Abstract] [Full Text] [Related]

  • 13. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.
    Giardina WJ, Williams M.
    CNS Drug Rev; 2001 Oct 05; 7(3):305-16. PubMed ID: 11607045
    [Abstract] [Full Text] [Related]

  • 14. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB, Lookingland KJ, Bédard PJ, Huff RM.
    J Pharmacol Exp Ther; 2005 Sep 05; 314(3):1248-56. PubMed ID: 15980060
    [Abstract] [Full Text] [Related]

  • 15. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb 05; 117(4):403-12. PubMed ID: 7604140
    [Abstract] [Full Text] [Related]

  • 16. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T.
    Synapse; 1997 Aug 05; 26(4):381-91. PubMed ID: 9215597
    [Abstract] [Full Text] [Related]

  • 17. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF, Ni L.
    J Pharmacol Exp Ther; 1998 Jan 05; 284(1):307-11. PubMed ID: 9435192
    [Abstract] [Full Text] [Related]

  • 18. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 05; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 19. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF, Sheng J.
    J Pharmacol Exp Ther; 1993 Jun 05; 265(3):1387-91. PubMed ID: 8099621
    [Abstract] [Full Text] [Related]

  • 20. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Belluzzi JD, Domino EF, May JM, Bankiewicz KS, McAfee DA.
    Mov Disord; 1994 Mar 05; 9(2):147-54. PubMed ID: 7910948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.